-

Eikon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery and development, today announced that CEO and Board Chair, Roger M. Perlmutter, M.D., Ph.D., will provide a business update highlighting pipeline and clinical development progress in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:00 AM Pacific Standard Time.

Additional information about Eikon Therapeutics can be found on the company’s website at: www.EikonTx.com.

About Eikon Therapeutics

Eikon Therapeutics seeks to advance breakthrough therapeutics through the purposeful integration of engineering and science. Our proprietary discovery technologies leverage Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to visualize and measure the real-time movement of proteins in living cells, with the goal of bringing important new medicines to people suffering from grievous illness. Eikon operates from its facilities in California, New Jersey, and New York and can be found online via our website or LinkedIn.

Contacts

Colin Sanford
colin@bioscribe.com

Industry:

Eikon Therapeutics, Inc.

Release Versions
English
Hashtags
#Biotech
#Biotechnology
#JPM2023

Contacts

Colin Sanford
colin@bioscribe.com

Social Media Profiles
Eikon on LinkedIn
Eikon Website
More News From Eikon Therapeutics, Inc.

Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting

MILLBRAE, Calif. & CHICAGO--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with traditional biology research to accelerate drug discovery, today announced that new data from its oncology programs will be presented in collaboration with independent investigators at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30 – June 3, 2025, in Chicago, Illinois. Alongside these present...

Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline

HAYWARD, Calif.--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug discovery and development, today announced the initial closing of a $350.7 million Series D financing. Since its founding in 2019, Eikon Therapeutics has privately raised in excess of $1.1 billion to support its mission of developing new medicines to address grievous illnesses. The financing round w...

Eikon Therapeutics Announces Nature Methods Publication Highlighting its Pioneering Oblique Line Scan Technology

HAYWARD, Calif.--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a clinical-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug discovery and development, today announced a new publication in Nature Methods detailing its Oblique Line Scan (OLS) technology which may be combined with Eikon's Single Molecule Tracking (SMT) platform, a high-throughput system enabling the rapid interrogation of new drug targets that reveals the...
Back to Newsroom